Overview
- Agenus executed an $85 million private placement that includes purchase warrants that could supply an additional $255 million if fully exercised, bringing potential gross proceeds to $340 million.
- The financing was led by Commodore Capital with participation from RA Capital, TCGX, Invus and Ligand and uses an initial share/pre‑funded warrant issuance plus two warrant tranches that create future dilution risk.
- The company said it will stop funding the BATTMAN late‑line metastatic study and redirect resources to ROBBIN, a planned registrational Phase 3 trial testing botensilimab plus balstilimab as neoadjuvant therapy for high‑risk Stage II/III MSS colon cancer.
- Agenus says ROBBIN’s design is aligned with the FDA, will enroll about 850 patients, plans first dosing in Q1 2027, expects interim pathologic‑response readouts in the second half of 2027, an interim event‑free‑survival analysis in 2029 and a final EFS readout in 2030.
- The company projects that full warrant exercise would extend its cash runway through 2031 whereas without exercise existing cash plus the $85 million would fund operations only into the third quarter of 2027, making the warrant decision a near‑term determinant of the program’s future.